Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Antihemophilic Factor Human Recombinant Action Pathway
Homo sapiens
Drug Action Pathway
Antihemophilic factor, human recombinant of the coagulation Factor VIII, also known as Advate, Adynovate, Helixate, Kogenate, Kovaltry, Novoeight, Recombinate, to treat hemophilia A, von Willebrand disease and Factor XIII deficiency. Antihemophilic factor, human recombinant is administered intravenously and acts to correct coagulation defects, by activating coagulation factor X and IX.
References
Antihemophilic Factor Human Recombinant Pathway References
Titheradge MA, Coore HG: Initial rates of pyruvate transport in mitochondria determined by an "inhibitor-stop" technique. Biochem J. 1975 Sep;150(3):553-6. doi: 10.1042/bj1500553.
Pubmed: 2157
Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ, et al.: Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med. 1990 Dec 27;323(26):1800-5. doi: 10.1056/NEJM199012273232604.
Pubmed: 2123300
Hsu HC, Chen YF, Ho CH: Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Zhonghua Yi Xue Za Zhi (Taipei). 1999 Jul;62(7):450-4.
Pubmed: 10418180
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings